NCT05231174

Brief Summary

With the increase in population and the rising prevalence of various diseases, the workload of disease diagnosis has sharply increased. The accessibility of healthcare services and long waiting times have become common issues in the public health medical system, with many primary patients having to wait for extended periods to receive medical services. There is an urgent need for rapid, accurate, and low-cost diagnostic services.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
535

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 29, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 9, 2022

Completed
1.2 years until next milestone

Study Start

First participant enrolled

May 1, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2023

Completed
Last Updated

January 19, 2024

Status Verified

January 1, 2024

Enrollment Period

3 months

First QC Date

January 29, 2022

Last Update Submit

January 17, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • AUROC of the self-evaluation tool

    The performance of the self-evaluation tool is evaluated with accuracy with reference to the diagnostic labels by senior ophthalmologists based on fundus photos.

    Immediately after using the chatbot

Study Arms (1)

A self-evlaution tool based on Large Language Model

EXPERIMENTAL

The self-evlaution tool, powered by a large language model, processes user queries through a comprehensive generation, decision, action, and safety framework to deliver optimal responses. The system's key features include retrieval-augmented in-context learning, which enhances the responses generated by sourcing information from reliable websites. It also incorporates a Guardrail module to mitigate potential harmful content in the responses by validating the content before delivery. Additionally, the system features a Self-checking memory module that maintains essential clinical characteristics across multi-turn dialogues, ensuring consistent and continuous interactions with users.

Other: A self-evlaution tool based on Large Language Model

Interventions

Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model. The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR.

A self-evlaution tool based on Large Language Model

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhognshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

Location

MeSH Terms

Conditions

DiseaseDiabetic Retinopathy

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsRetinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Study Officials

  • Yingfeng Zheng

    Zhongshan Ophthalmic Center, Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 29, 2022

First Posted

February 9, 2022

Study Start

May 1, 2023

Primary Completion

July 30, 2023

Study Completion

July 30, 2023

Last Updated

January 19, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations